VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

URLC10-CDCA1-KOC1 Multipeptide Vaccine

Vaccine Information

Vaccine Name: URLC10-CDCA1-KOC1 Multipeptide Vaccine
Target Pathogen: Cancer
Target Disease: Cancer
Vaccine Ontology ID: VO_0007071
Type: Multipeptide vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Host Species as Laboratory Animal Model: Human
LY6K gene engineering:
- Type: Recombinant protein preparation
- Description: (Rini et al., 2016)
- Detailed Gene Information: Click Here.
NUF2 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
IGF2BP3 gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
Preparation: The vaccine is co-delivered with GM-CSF (Rini et al., 2016).
Description: This is for Gastric Cancer (NCT00681577). A cancer vaccine containing multiple peptide epitopes with potential immunostimulatory and antitumor activities. Peptide epitopes in this vaccine are derived from, URLC10 (up-regulated lung cancer 10), CDCA1 (cell division cycle-associated protein 1), KOC1 (IGF II mRNA Binding Protein 3). Upon administration, URLC10-CDCA1-KOC1 multipeptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumor cells expressing URLC10, CDCA1, KCO1 peptides, resulting in cell lysis and decreased tumor growth (Rini et al., 2016; NCIT_C95212).

Host Response

References

NCIT_C95212: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C95212]

NCT00681577: Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer [https://clinicaltrials.gov/ct2/show/NCT00681577]

Rini et al., 2016: Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, Weikert S, Bracarda S, Crabb SJ, Bedke J, Ludwig J, Maurer D, Mendrzyk R, Wagner C, Mahr A, Fritsche J, Weinschenk T, Walter S, Kirner A, Singh-Jasuja H, Reinhardt C, Eisen T. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2016; 17(11); 1599-1611. [PubMed: 27720136].